Crohn's disease (CD) accounts for a variety of clinical manifestations or phenotypes that
stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is …

The current treatment of Crohn's disease is limited by a lack of long-term efficacy of
corticosteroid therapy and the associated side effects. Biological treatment strategies aimed …

Crohn's disease is a debilitating and expensive disease that is growing in incidence in both
developing and developed countries. While conventional therapies, such as corticosteroids …

Aliment Pharmacol Ther 2011; 33: 857–869 Summary Background Crohn's disease is a
progressive condition, with most patients developing a penetrating or stricturing …

Crohn's disease is a chronic, debilitating gastrointestinal disorder in which a variety of
cellular processes and pro‐inflammatory mediators influence the pathogenesis of the …

The recent licensing of anti‐TNFα antibody treatment offers the potential to radically alter the
course of severe Crohn's disease using genetically‐engineered drugs directed against a …

Crohn's disease is a chronic, relapsing and remitting inflammatory condition of the
gastrointestinal tract. Treatment has changed radically over the past decade with the …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

Background Crohn's disease may be refractory to conventional treatments such as
corticosteroids, enteral nutrition and immuno‐suppressive agents. A number of patients with …

Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of
inflammatory bowel diseases (IBD). However, the molecular mechanism of action of these …